Evaluation of CAIX and CAXII Expression in Breast Cancer at Varied O2 Levels: CAIX is the Superior Surrogate Imaging Biomarker of Tumor Hypoxia
暂无分享,去创建一个
[1] P H Watson,et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. , 2000, Cancer research.
[2] Xilin Sun,et al. Tumor Hypoxia Imaging , 2011, Molecular Imaging and Biology.
[3] C. Koch,et al. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)a cet amide] : analysis of drug adducts by fluorescent antibodies vs bound radioactivity. , 1995, British Journal of Cancer.
[4] Adrian L. Harris,et al. Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.
[5] Valerie A Longo,et al. Molecular Targeting of Carbonic Anhydrase IX in Mice with Hypoxic HT29 Colorectal Tumor Xenografts , 2010, PloS one.
[6] C. Ling,et al. Noninvasive molecular imaging of hypoxia in human xenografts: comparing hypoxia-induced gene expression with endogenous and exogenous hypoxia markers. , 2008, Cancer research.
[7] Johan Bussink,et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. , 2002, Cancer research.
[8] Robert J Gillies,et al. A mammaglobin-A targeting agent for noninvasive detection of breast cancer metastasis in lymph nodes. , 2011, Cancer research.
[9] Andrea Scozzafava,et al. Inhibition of carbonic anhydrase IX: a new strategy against cancer. , 2009, Anti-cancer agents in medicinal chemistry.
[10] J. Kaanders,et al. Accelerated radiotherapy with carbogen and nicotinamide (ARCON) for laryngeal cancer. , 1998, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[11] Andrew K. Dunn,et al. A Time Domain Fluorescence Tomography System for Small Animal Imaging , 2008, IEEE Transactions on Medical Imaging.
[12] M. Wei,et al. Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[13] J. Pastorek,et al. Cancer-associated carbonic anhydrases and their inhibition. , 2008, Current pharmaceutical design.
[14] S. Pastoreková,et al. Tumor-associated carbonic anhydrases and their clinical significance. , 2006, Advances in clinical chemistry.
[15] Shingo Matsumoto,et al. Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302 , 2015, Cancer & metabolism.
[16] C. Supuran,et al. Carbonic Anhydrases as Targets for Medicinal Chemistry , 2007 .
[17] A. Harris,et al. Carbonic anhydrase IX, an endogenous hypoxia marker, expression in head and neck squamous cell carcinoma and its relationship to hypoxia, necrosis, and microvessel density. , 2001, Cancer research.
[18] R. Gillies,et al. Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.
[19] J. Bussink,et al. Effects of nicotinamide and carbogen in different murine colon carcinomas: immunohistochemical analysis of vascular architecture and microenvironmental parameters. , 2004, International journal of radiation oncology, biology, physics.
[20] S M Evans,et al. Hypoxia and necrosis in rat 9L glioma and Morris 7777 hepatoma tumors: comparative measurements using EF5 binding and the Eppendorf needle electrode. , 2000, International journal of radiation oncology, biology, physics.
[21] C. Koch,et al. Prognostic significance of tumor oxygenation in humans. , 2003, Cancer letters.
[22] J. Pouysségur,et al. Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. , 2009, Cancer research.
[23] P. Lambin,et al. Imaging of CA IX with fluorescent labelled sulfonamides distinguishes hypoxic and (re)-oxygenated cells in a xenograft tumour model. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[24] Jongphil Kim,et al. The computation of bivariate normal and t probabilities, with application to comparisons of three normal means , 2013, Comput. Stat. Data Anal..
[25] P H Watson,et al. Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma , 2003, British Journal of Cancer.
[26] W. Oyen,et al. Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] A S Kennedy,et al. Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma. , 1998, Gynecologic oncology.
[28] R. Gillies,et al. Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction. , 2005, Analytical biochemistry.
[29] J. Vermorken,et al. Review: implications of in vitro research on the effect of radiotherapy and chemotherapy under hypoxic conditions. , 2007, The oncologist.
[30] M. Lerman,et al. Carbonic anhydrase 9 as an endogenous marker for hypoxic cells in cervical cancer. , 2001, Cancer research.
[31] C. Supuran,et al. Alternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotype , 2007, British Journal of Cancer.
[32] S M Evans,et al. Interlaboratory variation in oxygen tension measurement by Eppendorf “Histograph” and comparison with hypoxic marker , 1997, Journal of surgical oncology.
[33] K. Chayama,et al. Expression of VEGF‐C and VEGF‐D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma , 2004, Cancer science.
[34] Robert J Gillies,et al. Noninvasive Detection of Breast Cancer Lymph Node Metastasis Using Carbonic Anhydrases IX and XII Targeted Imaging Probes , 2011, Clinical Cancer Research.
[35] J. Humm,et al. Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. , 2007, The Lancet. Oncology.
[36] Johan Bussink,et al. Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[37] P. Sutphin,et al. Metabolic targeting of hypoxia and HIF1 in solid tumors can enhance cytotoxic chemotherapy , 2007, Proceedings of the National Academy of Sciences.
[38] J. Pastorek,et al. Carbonic anhydrase IX as an anticancer therapy target: preclinical evaluation of internalizing monoclonal antibody directed to catalytic domain. , 2010, Current pharmaceutical design.
[39] R. Gatenby,et al. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. , 1988, International journal of radiation oncology, biology, physics.
[40] Christophe Van de Wiele,et al. Molecular imaging of hypoxia with radiolabelled agents , 2009, European Journal of Nuclear Medicine and Molecular Imaging.
[41] Damien J. Ferraro,et al. Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer , 2011, Clinical Cancer Research.
[42] Trevor Hastie,et al. Gene Expression Programs in Response to Hypoxia: Cell Type Specificity and Prognostic Significance in Human Cancers , 2006, PLoS medicine.
[43] W. Sly,et al. Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. , 2001, The American journal of pathology.
[44] C. Supuran,et al. Hypoxia activates the capacity of tumor‐associated carbonic anhydrase IX to acidify extracellular pH , 2004, FEBS letters.
[45] G. Cook,et al. Oncological molecular imaging: nuclear medicine techniques. , 2003, The British journal of radiology.
[46] Claudiu T. Supuran,et al. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators , 2008, Nature Reviews Drug Discovery.
[47] M. Knopp,et al. PET/CT imaging of clear cell renal cell carcinoma with 124I labeled chimeric antibody , 2009, Therapeutic advances in urology.
[48] M C Weissler,et al. Hypoxia and vascular endothelial growth factor expression in human squamous cell carcinomas using pimonidazole as a hypoxia marker. , 1998, Cancer research.